Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Novartis AG (NVS - Snapshot Report) recently announced positive results from its phase III study, SPARK, spanning over 64 weeks.

The results showed that its candidate QVA149 was more effective at reducing all chronic obstructive pulmonary disease (COPD) exacerbations compared to Seebri Breezhaler (glycopyrronium bromide 50 mcg) and open-label Boehringer-Ingelheim/Pfizer’s (PFE - Analyst Report) Spiriva (tiotropium) 18 mcg.

We note that Novartis’ candidate QVA149 is being studied for the treatment of chronic obstructive pulmonary disease (COPD). The results were published in Lancet Respiratory Medicine. The study met its primary endpoint of significantly reducing the rate of moderate or severe COPD exacerbations.

It was also observed that usage of QVA149 can lead to significant improvements in lung function. SPARK is one of the ten studies, which is evaluating QVA49 for the treatment of COPD in the IGNITE phase III clinical trial program spanning across 42 countries and involving 7,000 patients.

We note that other than QVA149, Novartis’ COPD portfolio includes Onbrez Breezhaler (indacaterol maleate), which was launched in the US under the brand name Arcapta Neohaler and in Japan under the name Onbrez inhalation capsules where it is being co-promoted by Eisai and Co. Ltd (ESALY).

Onbrez Breezhaler reported a 39% year over year growth in 2012 driven by strong demand. As per Novartis, COPD affects approximately 210 million people across the globe and is expected to become the third most important cause of death by 2020. Thus, it provides ample commercial opportunities for the candidate upon approval.

Novartis currently carries a Zacks Rank #3. Right now, UCB SA (UCBJF) looks more attractive with a Zacks Rank #1 (Strong Buy).

 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%